

PATENT SPECIFICATION

(11) 1 328 641

1 328 641

NO DRAWINGS

- (21) Application No. 56132/70 (22) Filed 25 Nov. 1970
 (31) Convention Application No. 6 940 803 (32) Filed 26 Nov. 1969
 (31) Convention Application No. 7 010 548 (32) Filed 24 March 1970 in
 (33) France (FR)
 (44) Complete Specification published 30 Aug. 1973
 (51) International Classification A61K 7/00, 9/06
 (52) Index at acceptance A5B 755 75Y 764 771 774



(54) THERAPEUTIC AND COSMETIC COMPOSITIONS

(71) We, ORSYMONDE, a French Body Corporate, of 17 Faubourg Montmartre, Paris 9e, France, do hereby declare the invention for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—

The present invention relates to compositions for dermatological or cosmetic use, and more particularly, to compositions for the hygiene and protection of the skin, the teeth and the scalp.

In dermatology, active principles intended for external treatments of the skin and teguments are very frequently combined with a fatty excipient to give unguents, cerates, plasters or ointments.

The development of modern excipients has made it possible in many cases, both in dermatology and in cosmetology, to replace these fatty preparations, which stain and are not well absorbed by the skin, by creams of the oil-in-water emulsion type, which are valued because of their properties of being washable, of giving, after rubbing in, an invisible non-fatty film, and of penetrating easily into the skin.

However, the field of application of these creams is limited to biologically active substances which are stable in the presence of water, which excludes a large number of biologically active material, including many enzymes, antibiotics, organ extracts, hormones and the like, and combinations of biologically active materials which are incompatible in the presence of water.

Even with stable ingredients, aqueous creams can present certain disadvantages to the user, such as: the need to carry a bulky tube or pot if the material is to be applied several times daily, or is to be taken on a journey; and poor dosing of the active principles because the amount of cream applied by rubbing can vary greatly each time some is taken, depending on whether it is taken from a tube or from a pot.

These disadvantages, which restrict the field

of application of the creams, can be remedied by the present invention, which provides a composition produced by lyophilisation of an oil-in-water emulsion comprising:

(a) an active principle as hereinafter defined:

(b) a fatty acid or a salt or ester thereof, a fatty alcohol, or an ester thereof, or an animal, vegetable, mineral or synthetic fat or wax, which is solid at normal temperature and pressure but melts at a temperature not higher than 75°C.;

(c) a solution in water of a thickener; and

(d) an emulsifier.

The compositions of the invention can be added to water to give at the time of use an aqueous solution for dermatological or cosmetological use, such as a cream, lotion, milk or jelly, in which the active principle or principles are entirely preserved regardless of their stability in water.

Apart from questions of stability, the new compositions also provide greater ease of use, in out-patient treatment, of all the active materials which can be used in dermatology and in cosmetology, and allows them to be applied at well-defined unit doses.

The new compositions can optionally also contain customary ingredients, for example perfumes, dyestuffs, buffers and preservatives.

The lyophilised product is a solid, dry, spongy, non-hygroscopic but rather hydrophilic mass which gives, after brief immersion in water and as a result of rubbing onto the skin, a cream, jelly, milk or lotion for dermatological or cosmetological use.

The compositions can be in unit doses and may be in the form of extremely diverse shapes and sizes, e.g. parallelepipeds, cylinders, spheres, hemispheres, truncated cones and the like.

The term "active principle" as used herein includes both medicines for external use and cosmetic agents for the hygiene and protection of the skin, the mouth, the teeth and the hair, for example skin softeners, detergents, depilatories, deodorisers, soothing agents, anti-sun-

[Price 25p]

burn agents, anti-perspiration agents, anti-dandruff agents and antiseptics. The active principle may be, for example a corticosteroid, phenylbutazone, an antibiotic, an enzyme, a vitamin, or a vegetable or animal extract.

The lipid phase of the new compositions may contain at least one, and preferably several, of the following substances: fatty acids and their derivatives (salts and esters); fatty alcohols and their derivatives (esters); and complex fatty substances of animal, vegetable or synthetic origin, for example lanolins, paraffins or spermaceti; animal waxes, vegetable waxes and synthetic waxes.

The hydrophilic phase may contain as thickeners, for example, one of the following: natural gums (gum arabic, gum tragacanth and guar gum); cellulose derivatives; pectins (including derivatives of alginic acid and of carrageen); bentonites and colloidal silicas, polysaccharides; synthetic macromolecules (with vinyl or acrylic groups or the like); starchy materials; phosphorylated derivatives of aliphatic hydroxylic alcohols; and natural or semi-synthetic inter-esterified triglycerides.

As emulsifiers, the hydrophilic phase may contain: non-ionic substances, for example Tweens or Spans; anionic substances, for example lauryl sulphates, or cationic substances, for example quaternary ammonium compounds; organic polyelectrolytes, e.g. derivatives of alkylarylsulphonic acid, and organic or inorganic salts of stearic acid, and oxy-ethylenated fatty alcohols.

One or more of these materials can be used in varying amounts.

The new compositions may be prepared by i) mixing the components of the lipid phase (b), melting the phase by heating, homogenising it and adding the emulsifier thereto; ii) preparing the aqueous phase containing the thickener; iii) mixing the hot lipid phase with the aqueous phase at essentially the same temperature; iv) distributing the emulsion into cells having the desired shape and size for the desired unit dose and v) lyophilising the preparation contained in the cells, the active principle or principles being added to the composition during the formation of the emulsion or before distribution into the cells.

The active principles may be added during the formation of the emulsion, in which case the emulsion is poured hot into the cells, or, if the active principles are too labile to withstand an increase in temperature, the emulsion may be cooled, the active principles added and the emulsion then immediately distributed into the cells.

The cells containing the cooled preparation, are then frozen so that the temperature of the preparation is lowered approximately to between -18° and -40°C . It is subjected to freeze-drying or lyophilisation under a high vacuum at about 10^{-2} mm Hg, in such a way that the heat required for the sublimation of

the water is supplied while the temperatures does not rise to above the freezing point of the product.

The invention thus makes it possible to improve the physical characteristics, especially the consistency and the structure, of compositions for dermatological or cosmetological use, by combining the active principle or principles with the excipients quoted above.

Finally, the freezing conditions can be modified so as to vary the structure of the mass by changing the size of the crystals. For example, the freezing can be carried out on vibrating plates, moved by electromagnetic vibrations or ultrasonics.

After lyophilisation, the compositions obtained can be packaged in different ways for example in bulk, in boxes or tubes, or in unit sachets, or, finally, in a preferred presentation intended to facilitate their use, as described below.

After immersion in water, the particles of lyophilised product rapidly become soft and difficult to handle. To avoid this disadvantage, the particles of lyophilised product may be placed on a wide-mesh fabric screen which can neither resist the passage of water nor the passage of the reconstituted emulsion for application to the skin. This screen can consist of natural or synthetic fibres. It is advantageous to use heat-weldable fabrics, the use of which presents convenient features for industrial presentation.

The particles of lyophilised product contained in their individual sachet of permeable fabric can be protected in a sachet of paper or aluminium, by themselves or combined with a plastic film (for example of polyethylene). The sachets thus obtained can be packaged in varying numbers in cardboard containers or in another packaging material.

Presentation inside a natural or synthetic sponge is different from that of the textile sachet. Preferably, a synthetic sponge, such as polyurethane foam, is used. The foam is dipped into the liquid emulsion and becomes impregnated through compression followed by expansion *in situ*. The whole, consisting of the composition and the supporting foam, is lyophilised, the amount of emulsion absorbed being a function of the diameter and number of the pores and of the viscosity of the composition.

The invention makes it possible to produce compositions which are stable over a period of time or which contain molecules or substances which are unstable or incompatible in the presence of water. Suitable unstable substances include products of natural origin possessing a physiological activity which is dependent on the material not having deteriorated, and which is not preserved well over a period of time. Products of natural origin which can be used as they are or combined with stabilisers, and which are suitable, include especially: (a) mineral products, namely spa

muds and spa waters, oyster-bed muds, vegato-mineral muds, waters containing sulphur, sodium, calcium or magnesium, waters rich in trace elements, especially trace metal elements, waters containing iodine and bromine, and waters producing nascent sulphur; and (b) products of animal or vegetable origin, such as spa plankton, marine plankton, fish milt, algae and marine plants, shellfish, oysters and fish. These various products can be taken directly from their natural location and used as such, after dehydration by lyophilisation; they can, if desired, be combined with stabilisers. In media, the composition of which can be modified to increase the content of certain natural constituents, such as sulphur, iodine, trace elements, vitamins, aminoacids and radioactive products, to the desired extent.

The majority of shampoos and compositions for use on the hair, or for treatment of the scalp, are in a liquid form which suffers from the same disadvantages as those mentioned

above for cosmetic and dermatological compositions. The present invention makes it possible to produce lyophilised compositions useful as shampoos and for the treatment of the scalp containing physiologically active, unstable products.

The Examples which follow illustrate the invention.

Examples 1 to 4 relates to compositions for cosmetological use.

Examples 5 to 19 relate to compositions for dermatological use.

Examples 5 to 9 relate to active principles which are stable in the aqueous phase, but which can be more easily used as a result of the invention.

Examples 9 to 19 relate especially to active principles which are unstable or incompatible in the aqueous phase.

Examples 20 to 23 relate to compositions for treatment of the hair or scalp.

Example 24 relates to a preferred form of cream for external use.

EXAMPLE 1

Emollient Cleansing Cream

Lipid phase	Ethoxylated lanolin	1 g.
	Stearyl alcohol	3 g.
	Cetyl alcohol	3 g.
	Sodium lauryl sulphate	1 g.
	Palm oil sucroglyceride	1 g.
Aqueous phase	High viscosity carboxymethylcellulose	0.1 g.
	Lithium, sodium and magnesium triple fluosilicate	2.5 g.
	Methyl para-hydroxybenzoate	0.1 g.
	Rose water	20 g.
	Phosphoric acid	q.s.p. pH 5
	Purified water	q.s.p. 100 g.

Method of Preparation

1) The ethoxylated lanolin, the stearyl and cetyl alcohols and the palm oil sucroglyceride are melted together. The sodium lauryl sulphate is added and the mixture is heated to about 75°C.

2) Further, the high viscosity carboxymethylcellulose is swollen in the rose water until a translucent homogeneous gel is obtained.

3) The methyl *para* - hydroxybenzoate is dissolved hot in the total amount of purified water. The lithium, sodium and magnesium triple fluosilicate is added to this solution, with vigorous stirring. After half an hour, a homogeneous dispersion is obtained, to which phosphoric acid is added to adjust the pH to about 5.

4) The carboxymethylcellulose gel prepared under 2) and the lithium, sodium and magne-

sium triple fluosilicate dispersion prepared under 3) are mixed. The mixture is heated to 70°C.

5 5) The hot aqueous phase obtained under 4) is poured into the oil phase prepared under 1), while the latter is stirred.

6) An emulsion of the oil-in-water type is obtained which, after cooling, gives a cream.

10 7) This cream is distributed in cylindrical cells of diameter about 15 mm and depth about 10 mm, which each contain about 2 g. of cream.

15 8) All the cells are cooled in the cold chamber of a lyophilisation apparatus to a temperature of -35°C, after some hours. The cooling is then stopped. A vacuum is applied, and the heating of the plates of the apparatus, on which the cells have been placed, is begun. The temperature of the cells remains at between -10 and -25°C for several hours, while the temperature of the plates is raised from -40° to +5°C to +10°C. The vacuum

used during the process is about 10⁻² mm Hg.

The lyophilisation process is allowed to continue for at least 12 hours, and the plates are then heated to +20°C. When the temperature of the cells has reached equilibrium with that of the plates near 20°C, the lyophilisation can be considered complete. The vacuum in the apparatus is then released. The lyophilised masses are removed from the cells; they are placed on a strip of "Tergal" gauze and then covered with a strip of the same quality. The two strips of "Tergal" are sealed around the lyophilised masses, using an apparatus with resistance heaters, so that after cutting off, square sachets of 2 cm side lengths are obtained. These sachets are then placed beneath a polyethylene film, which is then heat-sealed.

In the examples which follow, the procedure of Example 1 is adopted to prepare the compositions described.

EXAMPLE 2

Deodorising and Anti-Perspiration Cream

Lipid phase	Stearic acid	6 g.
	Beeswax	1 g.
	Polyoxyethylene stearate	2 g.
	Polyoxyethylene and polyoxypropylene	
	Stearate	2 g.
	Lavender essence	0.25 g.
	Hexachlorophene	0.5 g.
Aqueous phase	Aluminogluconic acid	10 g.
	Hydroxyethylcellulose	0.25 g.
	Aluminium-magnesium double silicate	3 g.
	Distilled water	q.s.p. 100 g.

EXAMPLE 3

Cream to Prevent Sunburn

Lipid phase	{	Ethyl <i>p</i> -dimethylaminobenzoate	2 g.
		Stearyl alcohol	4 g.
		Stearic acid	1 g.
		Sodium lauryl sulphate	1 g.
		Coumarin	0.10 g.
		Titanium oxide	0.5 g.
		Neocolamin	0.5 g.
Aqueous phase	{	Yellow iron oxide	0.05 g.
		Propyl para-hydroxybenzoate	0.05 g.
		Starch	10 g.
		Colloidal silica	5 g.
		Aluminium-magnesium double silicate	2 g.
		Phosphoric acid	q.s.p. pH 7
		Distilled water	q.s.p. 100 g.

In this example, the starch replaces the cellulose derivative used in Example 1.

EXAMPLE 4

Hand Cream

Lipid phase	{	Glycerol monostearate	4 g.
		Lanolin alcohols	3 g.
		Stearic acid	1.5 g.
		Boric acid	2 g.
Aqueous phase	{	Methylcellulose	0.3 g.
		Polyethyleneglycol 4000	4 g.
		Lithium, sodium and magnesium triple fluosilicate	3 g.
		Lily of the Valley essence	0.01 g.
		Distilled water	q.s.p. 100 g.

EXAMPLE 5

Protective Cream for Dermatological Use

Lipid phase	Magnesium silicate	10 g.
	Zinc oxide	10 g.
	Polyglycol ether of saturated Fatty alcohols	5 g.
	Cetyl alcohol	5 g.
	Stearyl alcohol	5 g.
	Polyoxyethylene-sorbitane monostearate	1.5 g.
	Sorbitan monostearate	1 g.
Aqueous phase	Polyvinylpyrrolidone	2 g.
	Lithium, magnesium and sodium triple fluosilicate	3 g.
	Citric acid	q.s.p. pH 5.5
	Distilled water	q.s.p. 100 g.

EXAMPLE 6

Anti-Inflammation Cream Based on Corticosteroid

Lipid phase	Delta-hydrocortisone	0.5 g.
	Cetyl alcohol	3 g.
	Stearyl alcohol	3 g.
	Sodium lauryl sulphate	1 g.
Aqueous phase	Polyethyleneglycol 4000	2 g.
	Lithium, magnesium and sodium triple fluosilicate	2.5 g.
	Carboxyvinyl polymer	0.2 g.
	Phosphoric acid	q.s.p. pH 6
	Distilled water	q.s.p. 100 g.

In this example, the binder consists of a "CARBOPOL" carboxyvinyl polymer dispersed in water and then mixed with the gel of lithium, magnesium and sodium fluosilicate to form the base of the aqueous phase.

EXAMPLE 7

Antiseptic Cream

Lipid phase	{	Thymol	1 g.
		Salol	1.5 g.
		Menthol	0.5 g.
		Cetyl alcohol	10 g.
		Sodium lauryl sulphate	1 g.
Aqueous phase	{	Polyethyleneglycol 6000	2 g.
		Ethylhydroxyethylcellulose	0.2 g.
		Microcrystalline cellulose	0.1 g.
		Aluminium-magnesium double silicate	2 g.
		Lactic acid	q.s.p. pH 5
		Distilled water	q.s.p. 100 g.

EXAMPLE 8

Anti-Inflammation Cream

Lipid phase	{	Inter-esterified hydrogenated palm oil	5 g.
		Oxyethylenated fatty alcohols	5 g.
Aqueous phase	{	Carboxymethylcellulose H.V.	0.2 g.
		Lithium, magnesium and sodium trifluosilicate	2.5 g.
		Disodium phosphate	q.s.p. pH 8
		Distilled water	q.s.p. 100 g.
		Dextran sulphate	2 g.
		Sodium salt of phenylbutazone	4 g.

The method of preparation is as in Example 1; the active principles are added to the cooled cream.

EXAMPLE 9

Cream containing an Antibiotic and a Soluble Steroid

Lipid phase	Cetyl alcohol	5 g.
	Stearyl alcohol	5 g.
	Sodium dioctylsulphosuccinate	1.5 g.
	Polyoxyethylene lauryl ether	3 g.
	Ethylene oxide ether of lanolin alcohols	2 g.
Aqueous phase	Methyl <i>para</i> -hydroxybenzoate	0.1 g.
	Carboxymethylcellulose B.V.	0.2 g.
	Aluminium-magnesium double silicate	2.5 g.
	Disodium phosphate	q.s.p. pH 7
	Distilled water	q.s.p. 100 g.
	Sodium-chloramphenicol monosuccinate	0.15 g.
	Beta-methasone phosphate	0.10 g.

The excipient is prepared in accordance with the general process described in Example 1. The chloramphenicol salt and the beta-methasone salt are added to the cream obtained by cooling the emulsion, before distribution into cells.

EXAMPLE 10

Cream Combining Two Active Principles which are Incompatible in the

Aqueous Phase			
Lipid Phase	{	Cetyl alcohol	4 g.
		Stearyl alcohol	4 g.
		Sodium lauryl sulphate	1 g.
Aqueous phase	{	Lithium, magnesium and sodium triple fluosilicate	2.5 g.
		Carboxymethylcellulose B.V.	0.15 g.
		Polyethyleneglycol 4000	1 g.
		Phosphoric acid	q.s.p. pH 7
		Methyl <i>para</i> -hydroxybenzoate	0.1 g.
		Distilled water	q.s.p. 100 g.
		Hyaluronidase	15,000 U
	{	Heparinoid substance	5,000 U

The preparation is carried out in accordance with the process quoted in Example 1; the hyaluronidase and the heparinoid substance are added to the cooled cream just before distribution in to cells.

Examples 11 to 13 are prepared by the process of Example 1 using the basic formula quoted in Example 10, and the active ingredients noted below.

EXAMPLE 11

{	Hyaluronidase	15,000 U.
	Desoxymethasone	0.25 g.

EXAMPLE 12

{	Hyaluronidase	15,000 U.
	Tetracycline	2 g.
	Neutral sodium sulphite	0.1 g.

EXAMPLE 13

{	Alpha-mucase	1,500,000 U.
	Hydrocortisone	0.5 g.

The active principles in each of these Examples are added to the cooled cream immediately before its distribution into cells.

EXAMPLE 14

Lipid phase	{	Glycerol monostearate	2 g.
		Cetyl alcohol	2 g.
		Stearyl alcohol	2 g.
		Sodium lauryl sulphate	1 g.
Aqueous phase	{	Aluminium-magnesium double silicate	3 g.
		Propyl para-hydroxybenzoate	0.05 g.
		Sodium alginate	0.2 g.
		Polyethyleneglycol 6000	2 g.
		Disodium phosphate	0.5 g.
		Phosphoric acid	q.s.p. pH 7.5
		Distilled water	q.s.p. 100 g.
		Alpha-chymotrypsin	0.1 g.

After preparing the base excipient, as described for Example 1, the alpha-chymotrypsin is added before distributing the material into cells.

In Examples 15 and 16, the following active principles are added to the basic formulation of Example 14:

EXAMPLE 15

{	Heparinoid substance	5,000 U.
	Hyaluronidase	15,000 U.

EXAMPLE 16

{	Heparinoid substance	5,000 U.
	Hyaluronidase	15,000 U.
	Triamcinolone acetonide	0.1 g.

EXAMPLE 17

Cream containing a soluble stabilised penicillin salt

Lipid phase	Spermaceti		7.5 g.
	Sodium lauryl sulphate		1 g.
Aqueous phase	Lithium, magnesium, sodium triple fluosilicate		3 g.
	Carboxymethylcellulose B.V.		0.2 g.
	Polyethyleneglycol 4000		1 g.
	Monosodium phosphate		0.1 g.
	Disodium phosphate		0.5 g.
	Phosphoric acid	q.s.p. pH 7.5	
	Sodium tetracemate		0.2 g.
	Hexamine		1 g.
	Distilled water	q.s.p.	100 g.
	Sodium salt of penicillin		1,000,000 I.U.

EXAMPLE 18

Cream containing a soluble stabilised aureomycin salt

Lipid phase	Stearyl alcohol		7.5 g.
	Sodium lauryl sulphate		1 g.
Aqueous phase	Aluminium-magnesium double silicate		3 g.
	Ethylhydroxyethylcellulose		0.2 g.
	Sodium borate		2 g.
	Polyethyleneglycol 4000		2 g.
	Neutral sodium sulphite		0.2 g.
	Phosphoric acid	q.s.p. pH 6.8	
	Distilled water	q.s.p.	100 g.
	Aureomycin hydrochloride		2 g.

The aqueous gel obtained by the process described in Example 1 is prepared with part of the distilled water, and the remainder is used to make up a primary solution with the aureomycin hydrochloride, sodium borate and the sodium sulphite. This solution is added to the cooled emulsion of the oily phase in the aqueous phase.

EXAMPLE 19

Vitamin-containing cream with embryo extract

Lipid phase	{	Vitamin A	1,000,000 I.U.
		Vitamin F	2 g.
		Butylhydroxyanisole	0.1 g.
		Propyl gallate	0.1 g.
		Cetyl alcohol	7.5 g.
		Sodium lauryl sulphate	1 g.
Aqueous phase	{	Lithium, magnesium and sodium triple fluosilicate	3 g.
		Carboxymethylcellulose B.V.	0.2 g.
		Polyethylene glycol 4000	1 g.
		Citric acid	q.s.p. pH 5
		Methyl <i>para</i> -hydroxybenzoate	0.1 g.
		Propyl <i>para</i> -hydroxybenzoate	0.05 g.
		Nicotinamide	0.1 g.
		Pantothenyl alcohol	2.00 g.
		Distilled water	q.s.p. 100 g.
Fresh pulp of chicken embryos		5 g.	

The process is that quoted in Example 1; the fresh embryo pulp is added after cooling the emulsion, and just before the latter is distributed into cells.

EXAMPLE 20

Hair lotion containing lecithin and embryo extracts

Lipid phase	{	Palm oil sucroglyceride		2 g.
		Egg lecithin		0.5 g.
		Polyoxyethylenated lanolin		5 g.
		Saponin		5 g.
Aqueous phase	{	Salicylic acid		0.5 g.
		Pulp of fresh chicken embryos		5 g.
		Distilled water	q.s.p.	100 g.
		Eau de Cologne extract		1 g.

The saponin and the salicylic acid are dissolved in the water heated to 70°C, and the various constituents of the lipid phase are mixed at 70°C. The lipid phase is then emulsified in the hydrophilic phase and cooled. The embryo pulp and the perfume are added, and the emulsion is either divided amongst glass or plastic bottles, or amongst cells, frozen and lyophilised under the conditions previously described.

EXAMPLE 21

Shampoo with vitamin-containing enzymes

Lipid phase	{	Lipase		50,000 I.U.
		Vitamin F		1 g.
		Pantothenyl alcohol		2 g.
		Lavender oil		0.1 g.
Aqueous phase	{	Vitamin B6		1 g.
		Liquid Quillaya extract	q.s.p.	100 g.

EXAMPLE 22

Anti-dandruff lotion with antibiotic and steroid

An anti-dandruff lotion is made, using the procedure described in Example 20 from the following composition:

Lipid phase	—Beta-methasone		50 mg.
	{	Amphotericin B	100 mg.
		Sodium desoxycholate	80 mg.
		Disodium phosphate	20 mg.
		Monosodium phosphate	1.800 mg.
		Eau de Cologne extract	0.1 g.
Aqueous phase	Liquid Panama (bark) extract		q.s.p. 100 g.

as indicated above, an anti-dandruff lotion is obtained.

EXAMPLE 23

Shampoo for the treatment of baldness

The procedure described in Example 20 is applied to the following composition:

Lipid phase	{	Diethylstilboestrol	1 mg.
		Oestrone	0.02 m.g
		Hexachlorophene	0.5 g.
Aqueous phase	{	Cysteine	1 g.
		Witchhazel extract	10 g.
		Hop extract	10 g.
		Liquid extract of Quillaya	q.s.p. 100 g.

Lyophilised products, especially those made from sludges of natural waters and from plankton, may be prepared as described in Example 20.

EXAMPLE 24

Soothing dispersion cream contained in a porous support

A cream is prepared as described in Example 1 from the following composition:

Lipid phase	Cetyl alcohol	2 g.
	Stearyl alcohol	2 g.
	Sodium lauryl sulphate	0.5 g.
Aqueous phase	Lithium, magnesium and sodium fluosilicate	2.5 g.
	"Pluronic" F 68 (polyoxyethylene-polyoxypropanediol-1,2 marketed by Wyandotte)	1 g.
	Polyethyleneglycol (molecular weight 4000)	1 g.
	Carboxymethylcellulose of low viscosity	0.15 g.
	Distilled Water	q.s.p. 100 g.

Polyurethane foam having 10 to 100 pores per inch is used as the support. The foam is dipped while compressed into the fluid cream.

5 The expansion of the compressed foam in the cream allows the cream to be absorbed. The whole is then lyophilised by the process described above. For use, the foam is rapidly steeped in water and the material is applied

10 by rubbing over the skin.

The words "Span", "Tween", "Tergal" and "Pluronic" used throughout this Specification are Registered Trade Marks.

WHAT WE CLAIM IS:—

15 1. A composition produced by lyophilisation of an oil-in-water emulsion comprising: (a) an active principle as hereinbefore defined; (b) a fatty acid, or a salt or ester thereof, a fatty alcohol or an ester thereof, or an animal, vegetable, mineral or synthetic fat or wax, which is solid at normal temperature and pressure but melts at a temperature not higher than 75°C; (c) a solution in water of a thickener and (d) an emulsifier.

25 2. A composition according to claim 1, in which the said active principle is a corticosteroid, phenylbutazone, an antibiotic, an enzyme, a vitamin, a vegetable or animal extract, a skin softener, a detergent, a depilatory, a deodorant, an antiseptic, a soothing agent, an anti-sunburn agent, an anti-perspiration agent, or an anti-dandruff agent.

30 3. A composition according to claim 1 wherein the active principle is lipase, vitamin F, pantothenyl alcohol, vitamin B6, lavender oil or liquid extract of Quillaya.

4. A composition according to claim 1, 2 or 3 in which constituent (b) is a lanolin, paraffin wax or spermaceti.

5. A composition according to any one of claims 1 to 4, in which the thickener is a natural gum, cellulose derivative, alginic acid derivative, carrageen derivative, bentonite, colloidal silica, a polysaccharide, a starchy material, a triglyceride, or a phosphorylated derivative of a hydroxylic aliphatic alcohol.

6. A composition according to any of claims 1 to 5, in the form of a shaped unit dose.

7. A composition according to any of claims 1 to 6 incorporated within or into a natural or synthetic porous substrate.

8. A composition according to claim 1 substantially as described in any one of the foregoing Examples.

9. Process for the preparation of a composition according to claim 1 which comprises i) mixing the components of the lipid phase (b), melting the phase by heating, homogenising it and adding the emulsifier thereto; (ii) preparing the aqueous phase containing the thickener; (iii) mixing the hot lipid phase with the aqueous phase at essentially the same temperature; (iv) distributing the emulsion into cells having the desired shape and size for the desired unit dose and (v) lyophilising the preparation contained in the cells, the active principle or principles being added to the composition during the formation of the emulsion or before distribution into the cells.

10. Process according to claim 9, wherein the active principles are added during the

formation of the emulsion, and the emulsion is poured hot into the cells.

11. Process according to claim 9 wherein the emulsion obtained by carrying out steps i) to iii) in the absence of the active principles is cooled, the active principles are added and the emulsion is then immediately distributed into the cells.

12. Process according to claim 9, 10 or 11, wherein after distribution into the cells, the temperature of the preparation in the cells is lowered to between -18° and -40°C and the preparation is lyophilised at a pressure of the order of 10^{-2} mm Hg.

13. Process according to any of claims 9 to 12 substantially as hereinbefore described.

14. A composition produced by a process according to any of claims 9 to 13.

15. A cream, jelly, milk or lotion obtained by adding water to a composition as claimed in any of claims 1 to 8 and 14.

J. A. KEMP & CO.,
Chartered Patent Agents,
14, South Square, Gray's Inn,
London, W.C.1.

Printed for Her Majesty's Stationery Office by the Courier Press, Leamington Spa, 1973.
Published by the Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.